Pfizer has racked up a positive slate of Phase III data for its anti-inflammatory JAK1 inhibitor abrocitinib (PF-04965842), which the pharma giant is hoping to steer to the FDA relatively soon as it looks to get into a heated blockbuster race that’s been heavily overshadowed by new safety warnings for the class.
Copyright © 2021,